HC Wainwright Reiterates Buy Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a report issued on Monday,Benzinga reports. They presently have a $20.00 target price on the stock.

Separately, Wedbush restated an “outperform” rating and set a $11.00 target price on shares of Aprea Therapeutics in a report on Tuesday, August 13th.

Aprea Therapeutics Stock Down 3.0 %

APRE stock opened at $3.25 on Monday. The company has a market cap of $17.65 million, a price-to-earnings ratio of -1.16 and a beta of 0.97. The business has a fifty day simple moving average of $3.34 and a 200-day simple moving average of $3.89. Aprea Therapeutics has a 52 week low of $2.15 and a 52 week high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.64) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.11. The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. As a group, analysts expect that Aprea Therapeutics will post -2.56 earnings per share for the current fiscal year.

Insider Activity at Aprea Therapeutics

In other news, Director Marc Duey acquired 30,000 shares of the business’s stock in a transaction on Wednesday, October 16th. The shares were purchased at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the acquisition, the director now directly owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This represents a 14.28 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bernd R. Seizinger bought 10,000 shares of the company’s stock in a transaction dated Friday, October 11th. The shares were acquired at an average cost of $2.68 per share, for a total transaction of $26,800.00. Following the completion of the transaction, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. The trade was a 28.79 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 42,290 shares of company stock worth $165,096. 12.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aprea Therapeutics

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned approximately 0.20% of Aprea Therapeutics at the end of the most recent quarter. 34.19% of the stock is owned by institutional investors.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.